QS Corrections & Removals Require Strong Customer Advocacy – Exec
This article was originally published in The Gray Sheet
Executive Summary
Creation of a multi-discipline "customer advocacy team" to handle all non-sales calls can help device firms foresee and prepare for potential product or quality system problems, Alaris Medical Systems VP-Quality & Regulatory Affairs Bill Murphy suggested at RAPS' recent medical device conference
You may also be interested in...
Budget Crunch Forces CDRH To Abbreviate Baseline Device GMP Inspections
CDRH plans to dramatically increase its inspections of domestic medical device facilities performed this year by reviewing only two of the four major QSIT subsystems in each "baseline" audit.
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.